The expression of resistin in adipose tissues of patients with polycystic ovary syndrome and insulin resistance

Abstract

The relationship between the expression of resistin in polycystic ovary syndrome (PCOS) and insulin resistance was investigated. The plasma resistin concentrations in 35 patients with PCOS and 40 controls were measured by ELISA. Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and fasting insulin (FIN) were tested by radioimmunoassay. Insulin resistance index (HOMA-IR) was calculated. Fasting plasma glucose (FPG) was determined by oxidase test. Western blot and reverse transcriptase PCR (RT-PCR) methods were used to detect the expression of resistin in adipose tissues. The levels of plasma resistin, LH, LH/FSH and FIN and HOMA-IR in patients with PCOS were significantly higher than those in control group (all P<0.05). Plasma resistin was correlated positively with FPG, FIN, HOMA-IR, LH and LH/FSH (r=0.56, 0.60, 0.65, 0.48, and 0.42 respectively). Resistin protein and mRNA expression levels in patients with PCOS were significantly higher than those in normal tissues (all P<0.01). It was concluded that resistin might be involved in the pathogenesis of insulin resistance of PCOS.

Keywords

polycystic ovary syndrome / resistin / fasting plasma glucose / fasting insulin / insulin resistance

References

[1] BurghenG.A., GivensJ.R., KitabchiA.E.. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab, 1980, 50(1): 113-116

[2] ChangR.J., NakamuraR.M., JuddH.L., et al.. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab, 1983, 57(2): 356-359

[3] ShoupeD., KumarD.D., LoboR.A.. Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol, 1983, 147(5): 588-592

[4] NestlerJ.E., JakubowiczD.J., EvansW.S., et al.. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med, 1998, 338(26): 1876-1880

[5] SturrockN.D., LannonB., FayT.N.. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol, 2002, 53(5): 469-743

[6] DunaifA., GreenG., PhelpsR.G., et al.. Acanthosis nigricans, insulin action and hyperandrogenism: clinical, histological and biochemical findings. J Clin Endocrinol Metab, 1991, 73(3): 590-595

[7] SteppanC.M., BaileyS.T., BhatS., et al.. The hormone resistin links obesity to diabetes. Nature, 2001, 409(6818): 307-312

[8] Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group.. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004, 19(1): 41-47

[9] MathewsD.R., HoskerJ.P., RudenskiA.S., et al.. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28(7): 412-419

[10] SeowK.M., JuanC.C., HoL.T., et al.. Adipocyte resistin mRNA levels are down-regulated by laparoscopic ovarian electrocautery in both obese and lean women with polycystic ovary syndrome. Hum Reprod, 2007, 22(4): 1100-1106

[11] LegroR.S., StraussJ.F.. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril, 2002, 78(3): 569-576

[12] SteppanC.M., LazarM.A.. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab, 2002, 13(1): 18-23

[13] BarbD., WadhwaS.G., KratzschJ., et al.. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J Clin Endocrinol Metab, 2005, 90(9): 5324-5328

[14] BanksW.A., WilloughbyL.M., ThomasD.R., et al.. Insulin resistance syndrome in the elderly: assessment of functional, biochemical, metabolic, and inflammatory status. Diabetes Care, 2007, 30(9): 2369-2373

[15] RajalaM.W., ObiciS., SchererP.E., et al.. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest, 2003, 111(2): 225-230

[16] McTernanC.L., McTernanP.G., HarteA.L., et al.. Resistin, central obesity and type 2 diabetes. Lancet, 2002, 359(9300): 46-47

[17] SavageD.B., SewterC.P., KlenkE.S., et al.. Resistin/FIZZ3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes, 2001, 50(10): 2199-2202

[18] SeowK.M., JuanC.C., WuL.Y., et al.. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod, 2004, 19(1): 48-53

[19] WangH., ChuW.S., HemphillC., et al.. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab, 2002, 87(6): 2520-2524

[20] OttoC., OttoB., GokeB., et al.. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest, 2006, 29(3): 231-236

[21] SentinelliF., RomeoS., ArcaM., et al.. Human resistin gene, obesity and type 2 diabetes: mutation analysis and population study. Diabetes, 2002, 51(3): 860-862

[22] SpicgelmanB.M.. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes, 1998, 47(4): 507-514

[23] LingC., KindblomJ., WennboH., et al.. Increased resistin expression in the adipose tissue of male prolactin transgenic mice and in male mice with elevated androgen levels. FEBS Lett, 2001, 507(2): 147-150

[24] NestlerJ.E., BarlasciniC.O., CloreJ.N., et al.. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab, 1988, 66(1): 57-61